Takeda Pharmaceutical Company Limited

TAK · NYSE
Analyze with AI
Key StatsIncome StatementBalance SheetCash Flow
AnnualQuarterly
KMB
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Revenue$4,581,551,000$4,263,762,000$4,027,478,000$3,569,006,000
% Growth7.5%5.9%12.8%–
Cost of Goods Sold$1,580,217,000$1,431,505,000$1,244,072,000$1,106,846,000
Gross Profit$3,001,334,000$2,832,257,000$2,783,406,000$2,462,160,000
% Margin65.5%66.4%69.1%69%
R&D Expenses$730,227,000$729,924,000$633,325,000$526,087,000
G&A Expenses$0$0$0$0
SG&A Expenses$1,104,766,000$1,053,819,000$997,309,000$886,361,000
Sales & Mktg Exp.$0$0$0$0
Other Operating Expenses$823,755,000$834,439,000$662,267,000$588,867,000
Operating Expenses$2,658,748,000$2,618,182,000$2,292,900,000$2,001,315,000
Operating Income$342,586,000$214,075,000$490,505,000$460,844,000
% Margin7.5%5%12.2%12.9%
Other Income/Exp. Net-$167,502,000-$161,284,000-$115,415,000-$158,273,000
Pre-Tax Income$175,084,000$52,791,000$375,090,000$302,571,000
Tax Expense$66,941,000-$91,406,000$58,052,000$72,405,000
Net Income$107,928,000$144,067,000$317,017,000$230,059,000
% Margin2.4%3.4%7.9%6.4%
EPS34.1746.05102.1573.57
% Growth-25.8%-54.9%38.8%–
EPS Diluted33.6245.58100.9772.94
Weighted Avg Shares Out3,210,7103,128,9003,103,6183,127,002
Weighted Avg Shares Out Dil3,210,7103,160,6863,139,7443,154,338
Supplemental Information––––
Interest Income$19,638,000$78,097$5,508,000$4,591,000
Interest Expense$137,311,000$1,062,438$116,973,000$122,432,000
Depreciation & Amortization$761,396,000$644,461,000$664,400,000$583,151,000
EBITDA$1,210,512,000$1,143,936,000$1,284,067,000$1,183,213,000
% Margin26.4%26.8%31.9%33.2%